Agaverdiev Murad, Shamsov Bedil, Mirzoev Sorbon, Vardikyan Andranik, Ramirez Manuel Encarnacion, Nurmukhametov Renat, Beilerli Aferin, Zhang Bohan, Gareev Ilgiz, Pavlov Valentin
Department of Urology, Bashkir State Medical University, 450008, Ufa, Russian Federation.
Department of Urology, City Clinical Hospital, №21, 450071, Ufa, Russian Federation.
Noncoding RNA Res. 2022 Dec 19;8(2):146-154. doi: 10.1016/j.ncrna.2022.12.003. eCollection 2023 Jun.
The stromal vascular fraction (SVF) is a heterogeneous population of cells that, interacting with each other, can affect the processes of regeneration, angiogenesis, and immunomodulation. Over the past 20 years, there has been a trend towards an increase in the number of clinical studies on the therapeutic use of SVF. MicroRNAs (miRNAs) are also important regulators of cellular function and they have been shown to be involved in SVF cellular component function. The purpose of this study was to analyze existing clinical studies on the therapeutic use of SVF including the role of miRNAs in the regulation of the function of the cellular component of SVF as an anti-inflammatory, pro-angiogenic and cell differentiation activity.
The search strategy was to use material from the clinicaltrials.gov website, which focused on the key term "Stromal vascular fraction", and the inclusion and exclusion criteria were divided into two stages.
By August 2022, there were 149 registered clinical trials. Most studies belong to either Phase 1-2 (49.37%), Phase 1 (25.32%) or Phase 2 (22.78%). Most of them focused in the fields of traumatology, neurology/neurosurgery, endocrinology, vascular surgery, and immunology. However, only 8 clinical trials had published results. All of clinical trials have similar preparation methods and 8 clinical trials have positive results with no serious adverse effects.
There appears to be a wide potential for the clinical use of SVF without reports of serious side effects. Many preclinical and clinical studies are currently underway on the use of SVF, and their future results will help to further explore their therapeutic potential. Nevertheless, there are not many studies on the role of miRNAs in the SVF microenvironment; however, this topic is very important for further study of the clinical application of SVF, including safety, in various human diseases.
基质血管成分（SVF）是一群异质性细胞，它们相互作用，可影响再生、血管生成和免疫调节过程。在过去20年中，关于SVF治疗用途的临床研究数量呈上升趋势。微小RNA（miRNA）也是细胞功能的重要调节因子，已被证明参与SVF细胞成分的功能。本研究的目的是分析关于SVF治疗用途的现有临床研究，包括miRNA在调节SVF细胞成分功能中的作用，如抗炎、促血管生成和细胞分化活性。
检索策略是使用clinicaltrials.gov网站的资料，重点关注关键词“基质血管成分”，纳入和排除标准分为两个阶段。
截至2022年8月，有149项注册临床试验。大多数研究属于1-2期（49.37%）、1期（25.32%）或2期（22.78%）。其中大多数集中在创伤学、神经学/神经外科、内分泌学、血管外科和免疫学领域。然而，只有8项临床试验发表了结果。所有临床试验的制备方法相似，8项临床试验结果为阳性，且无严重不良反应。
SVF临床应用似乎具有广泛潜力，且无严重副作用报告。目前正在进行许多关于SVF使用的临床前和临床研究，其未来结果将有助于进一步探索其治疗潜力。然而，关于miRNA在SVF微环境中作用的研究并不多；然而，这一主题对于进一步研究SVF在各种人类疾病中的临床应用，包括安全性，非常重要。
Zotero 插件
